ADAM 12 as a first‐trimester maternal serum marker in screening for Down syndrome

Laigaard, Jens; Spencer, Kevin; Christiansen, Michael; Cowans, Nicholas J.; Larsen, Severin Olesen; Pedersen, Bent Nørgaard; Wewer, Ulla M.

doi:10.1002/pd.1540

Cited by 65 publications

(43 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ethnic differences seen in Table 2 have also been confirmed in the first-trimester (Laigaard et al, 2006b) and these differences should be taken into account when organizing the risk algorithm, but even though the analysis is based on only three DS pregnancies among Afro-Caribbeans, it seems as though ADAM 12 still discriminates between DS and normal pregnancies. In this regard, the size of the increase in ADAM 12 in Afro-Caribbean pregnancies is very similar to that seen with PAPP-A (Spencer et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

“…6.0 (Insightful Corp, USA). All ADAM 12 concentration values were converted to a multiple of the median (MoM) for unaffected pregnancies at the same gestational age using a previously defined third order polynomial of the form Median ADAM 12 ug/L = 0.0009 * GA ∧ 3-0.2206 * GA ∧ 2 + 14.721 * GA − 82.755 with GA being gestational age in days (Laigaard et al, 2006b). Correction of each MoM for maternal weight was performed by using a correction formula derived by log-regression.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

ADAM 12 as a second‐trimester maternal serum marker in screening for Down syndrome

et al. 2007

Self Cite

View full text Add to dashboard Cite

Background ADAM 12 is a placenta-derived glycoprotein that is involved in growth and differentiation. The maternal serum concentration of ADAM 12 is a potential first-trimester maternal serum marker of Down syndrome (DS). Here we examine the potential of ADAM 12 as a second-trimester maternal serum marker of DS. Materials and MethodsThe concentration of ADAM 12 was determined in gestational week 14-19 in 88 DS pregnancies and 341 matched control pregnancies. Medians of normal pregnancies were established by polynomial regression and the distribution of log 10 MoM ADAM 12 values in DS pregnancies and controls determined. Correlations with alpha-fetoprotein (AFP) and free β-human chorionic gonadotrophin (free β-hCG) were established and used to model the performance of maternal serum screening with ADAM 12 in combination with other second-trimester serum markers. ResultsThe ADAM 12 maternal serum concentration was significantly increased with a median MoM of 1.85 and a mean log 10 MoM (SD) of 0.268 (0.2678) compared to a mean log 10 MoM (SD) of 0.013 (0.4318) in controls. ADAM 12 correlated with maternal weight and ethnicity (with the serum concentration increased in Afro-Caribbeans), but neither with maternal age nor gestational age, and only marginally with AFP (r(DS) = 0.078, r(controls) = 0.093) and free β-hCG (r(DS) = 0.073, r(controls) = 0.144. The increase in detection rate-for a false positive rate of 5%-by adding ADAM 12 to the double test (AFP + free β-hCG) was 4%, similar to that of adding uE3 to the double test.Conclusion ADAM 12 is an efficient second-trimester marker for DS. Further studies should be conducted to determine whether it may be a useful additonal or alternative marker to those currently used in the secondtrimester.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

ADAM 12 as a second‐trimester maternal serum marker in screening for Down syndrome

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…When first investigated in the maternal circulation using a small series of samples on a quantitative enzyme-linked immunosorbent assay (ELI-SA), ADAM-12 appeared to be an extremely promising marker for chromosomal aneuploides, with markedly reduced levels of the molecule in affected first-trimester trisomies 21 and 18 maternal serum [19,20] . Later studies, using a new DELFIA platform (PerkinElmer Life Sciences, Turku, Finland), supported these early results, placing the discriminatory power of ADAM-12 greatest prior to 10 weeks' gestation [21][22][23][24][25] . In the second trimester, ADAM-12 levels were found to be increased in trisomy-21 pregnancies [26,27] .…”

Section: Adam-12 In Adverse Pregnancy Outcomesmentioning

confidence: 56%

Maternal Serum ADAM-12 as a Potential Marker for Different Adverse Pregnancy Outcomes

Matwejew

Cowans²,

Stamatopoulou³

et al. 2010

Fetal Diagn Ther

View full text Add to dashboard Cite

Objective: To investigate first-trimester ADAM-12 levels in pregnancies which later develop hypertensive and growth complications. Methods: First-trimester serum samples (11⁺⁰ to 13⁺⁶ weeks) were retrieved from frozen storage. 47 samples with at least one of the following adverse outcomes: pre-eclampsia (PE), small for gestational age, HELLP syndrome and gestational hypertension were analysed and 452 controls matched to the cases by gestational age and length of storage were analysed. ADAM-12 levels were measured by the automated AutoDELFIA immunoassay platform. Results: ADAM-12 was found to increase with gestational age (11⁺⁰ to 13⁺⁶ weeks) and decrease with increasing maternal weight and in women who smoked. After correction, ADAM-12 median multiples of the median were increased in cases with HELLP syndrome, all PE and PE only. Conclusion: The increased first-trimester levels of ADAM-12 in PE and HELLP are in contrast with previous findings. The usefulness of ADAM-12 as a marker for adverse outcomes is still unclear.

show abstract

“…ADAM-12 is also expressed by activated hepatic stellate cells (LePabic et al, 2003). ADAM-12 is present in higher amounts in maternal serum during pregnancy (Laigaard et al, 2006).…”

Section: Expressionmentioning

confidence: 98%

“…Indeed, ADAM-12 is able to cleave Insulin-like Growth Factor Binding Protein-3 and-5 (IGFBP-3 and IGFBP-5). The release of increasing concentrations of bioavailable IGF through IGFBP cleavage is important during pregnancy for foetal growth (Laigaard et al, 2006). ADAM-12 is also able to cleave membrane-bound Heparin-binding EGF-like Growth Factor (HB-EGF) (Asakura et al, 2002).…”

Section: Functionmentioning

confidence: 99%

ADAM12 (ADAM metallopeptidase domain 12 (meltrin alpha))

Rocks¹,

Cataldo²

2011

Atlas of Genetics and Cytogenetics in Oncology and Haematology

View full text Add to dashboard Cite

show abstract

ADAM 12 as a first‐trimester maternal serum marker in screening for Down syndrome

Cited by 65 publications

References 28 publications

ADAM 12 as a second‐trimester maternal serum marker in screening for Down syndrome

ADAM 12 as a second‐trimester maternal serum marker in screening for Down syndrome

Maternal Serum ADAM-12 as a Potential Marker for Different Adverse Pregnancy Outcomes

ADAM12 (ADAM metallopeptidase domain 12 (meltrin alpha))

Contact Info

Product

Resources

About